Highlights

  • Multiple ASX small-cap stocks recorded double-digit intraday gains, led by strong updates and project developments.
  • LTR Pharma Limited surged over 23% following positive Phase II clinical data.
  • Exploration-driven momentum lifted Infini Resources Limited, Litchfield Minerals Limited, Bindi Metals Limited, and Desert Minerals Limited.

A cluster of ASX-listed small-cap stocks recorded notable gains during today’s Trading session, with price movements reflecting intraday activity rather than closing levels. These gains appear to be driven by a mix of clinical, exploration, and strategic updates, reinforcing the sensitivity of micro-cap stocks to news flow.

The stocks in focus—LTR Pharma, Infini Resources, Litchfield Minerals, Bindi Metals, and Desert Minerals—span healthcare and resources, yet share a common theme: milestone-driven investor interest.

LTR Pharma (ASX:LTP): Clinical Data Drives 23% Surge

LTR Pharma Limited emerged as a significant performer, with its share price rising 23.456% intraday to $0.500.

The rally followed the release of interim Phase II data for its lead product SPONTAN®, which demonstrated a rapid onset of action with a median Tmax of 10 minutes—significantly faster than traditional oral alternatives. The data also confirmed a consistent safety profile and addressed key regulatory requirements for the US FDA pathway.

Importantly, the update strengthens the company’s planned 505(b)(2) regulatory strategy in the United States, positioning the drug for potential accelerated development. Investors appear to have responded positively to both the clinical validation and regulatory clarity.

Infini Resources (ASX:I88): Uranium Exploration Momentum

Infini Resources Limited recorded a 17.647% gain, with its share price reaching $0.200 during the session.

The move follows the company’s quarterly update, which highlighted encouraging assay results from Phase 2 drilling at the Portland Creek Uranium Project in Canada. Mineralisation was confirmed across multiple drillholes over a kilometre-scale area, supporting the presence of a structurally controlled hydrothermal system.

Additionally, expanded exploration footprints at both Portland Creek and Reitenbach Lake, alongside a planned maiden drilling campaign, have strengthened the company’s project pipeline. The scale of identified uranium anomalism across a 15 km corridor further underpins investor interest.

Litchfield Minerals (ASX:LMS): Exploration Success and Strategic Backing

Litchfield Minerals Limited delivered one of the strongest intraday performances, rising 46.249% to $0.585.

The surge follows its recent quarterly update, which outlined significant progress at the Oonagalabi Project in the Northern Territory. Notably, strong drilling results confirmed thick copper-zinc mineralisation, including intercepts of up to 128 metres.

A major catalyst has been the company’s selection into the BHP Xplor 2026 program, securing US$500,000 in non-dilutive funding along with technical support. This strategic backing enhances the credibility of its exploration model and provides additional resources to advance drilling and geophysical work.

The combination of high-grade results and external validation appears to have driven strong investor Demand.

Bindi Metals (ASX:BIM): Gold Exploration Gains Traction

Bindi Metals Limited saw its share price rise 14.285% to $0.160 during the Trading session.

The movement follows the announcement of strong induced polarisation (IP) survey results at the Ravni Project in Serbia. The company identified up to 2 kilometres of strike length anomalies, closely associated with known high-grade gold mineralisation at Drenjak and Rujak.

These anomalies, with chargeability values exceeding 40–60 mV/V, suggest the presence of sulphide-rich zones at depth—often linked to gold mineralisation in epithermal systems.

With drilling permits secured and a maiden drilling campaign set to commence in May 2026, the update has provided a clear near-term catalyst, contributing to the stock’s upward momentum.

Desert Minerals (ASX:DSM): Dual Commodity Strategy Supports Gains

Desert Minerals Limited also recorded a 12.244% increase, with its share price reaching $0.275 intraday.

Investor interest appears linked to progress across both its gold and lithium Assets. At the Mt Monger Gold Project, the company initiated a large-scale soil sampling program aimed at identifying concealed mineralisation.

Meanwhile, drilling has commenced at the Scotty Lithium Project in Nevada, targeting near-surface lithium zones with the aim of progressing toward a maiden resource estimate.

The combination of exposure to gold and lithium—two widely tracked commodities—alongside active exploration programs, has positioned the company on investors’ radar.

Sector-Wide Trend: News-Driven Momentum in Microcaps

Today’s price action highlights a broader trend within the ASX small-cap segment, where stocks often react sharply to operational updates. Unlike large-cap equities, where valuation metrics and macro factors dominate, micro-cap stocks tend to be highly sensitive to exploration results, clinical milestones, and funding developments.

Across all five companies, a common thread emerges: tangible progress. Whether it is clinical data validation, drilling results, geophysical anomalies, or strategic partnerships, each update has provided incremental evidence supporting future growth potential.

Conclusion

A group of ASX small-cap stocks—LTR Pharma, Infini Resources, Litchfield Minerals, Bindi Metals, and Desert Minerals—recorded strong intraday gains, driven by a mix of clinical breakthroughs, exploration success, and strategic developments. While each company operates in different sectors, the common driver behind today’s rally is clear: meaningful progress updates that have strengthened investor confidence. As these companies move into the next phase of development, their share performance will remain closely tied to execution and upcoming results.